Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML intergroup

Blood

Volumn 102, Issue 2, 2003, Pages 462-469

  Delaunay, Jacques ^b   Vey, Norbert ^b   Leblanc, Thierry ^b   Fenaux, Pierre ^b   Rigal Huguet, Françoise ^b   Witz, Francis ^b   Lamy, Thierry ^b   Auvrignon, Anne ^b   Blaise, Didier ^b   Pigneux, Arnaud ^b   Mugneret, Francine ^b   Bastard, Christian ^b   Dastugue, Nicole ^b   Van den Akker, Jacqueline ^b   Fière, Denis ^b   Reiffers, Josy ^b   Castaigne, Sylvie ^b   Leverger, Guy ^b   Harousseau, Jean Luc ^b   Dombret, Hervé ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHROMOSOME ABERRATION; CORRELATION ANALYSIS; CYTOGENETICS; DRUG MEGADOSE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REMISSION; RISK FACTOR; SURVIVAL; THROMBOCYTE COUNT;

EID: 0038156371     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3527     Document Type: Article

References (44)

1. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene. 2002;21:3377-3390.
2. Friedman AD. Leukemogenesis by CBF oncoproteins. Leukemia. 1999:13:1932-1942
3. Kundu M, Liu PP, Function of the inv(16) fusion gene CBFB-MYH11. Curr Opin Hematol. 2001;8:201-205.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
5. Quesnel B, Kantarjian H, Bjergaard JR et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol. 1993;11:2370-2379.
6. Fröhling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002;20:2480-2485.
7. Guerrasio A, Pilatrino C, De Micheli D, et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002;16:1176-1181.
8. Hiebert SW, Lutterbach B, Amann J. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins. Curr Opin Hematol. 2001;8:197-200.
9. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983;309:630-636.
10. Haferlach T, Winkemann M, Loffler H, et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization. Blood. 1996;87:2459-2463.
11. Mariton P, Keating M, Kantarjian H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995;9:965-971.
12. Wong KF, Kwong YL. Trisomy 22 in acute myeloid leukemia: a marker for myeloid leukemia with monocytic features and cytogenetically cryptic inversion 16. Cancer Genet Cytogenet. 1999;109:131-133.
13. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
14. Longley BJ, Reguera MJ, Ma Y. Classes of C-kit activating mutations; proposed mechanisms of action and implication for disease classification and therapy. Leuk Res. 2001;25:571-576.
15. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
16. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
17. Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80:2191-2198.
18. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
19. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18:768-780.
20. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-400.
21. Razzouk BI, Raimondi SC, Srivastava DK, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia. 2001;15:1326-1330.
22. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517-3523.
23. Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol. 2002;20:2774-2782.
24. Castaigne S, Archimbaud E, Bordessoule D, et al. Sequential induction or double induction chemotherapy increase disease-free survival compared to "3+7" chemotherapy in less than 50 years adults with acute myeloid leukemia [abstract]. Blood. 1996;88(suppl 1):291a.
25. Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 1996;10:1874-1882.
26. Reiffers J, Stoppa AM, Huguet F, et al. Autologous versus allogeneic stem cell transplantation in adults with acute myeloid leukemia (AML) in first remission (BGMT 91 protocol). Exp Hematol. 1997;25:788.
27. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978-2986.
28. Harousseau JL, Witz F, Lioure B, et al. Prognostic factors in adult patients with do novo AML. Preliminary results of the GOELAM-2 trial [abstract]. Blood. 2000:96(suppl 1):324a.
29. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mitelman F, ed. Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1991:1-53.
30. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972;135:185-206.
33. Hilsenbeck SG, Clark GM. Practical P-value adjustment for optimally selected cut-points. Stat Med. 1996;15:103-112.
34. Cox D. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
35. Gooley T, Leisenring W, Crowley J, Storer BE. Why Kaplan-Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York, NY: Marcel Dekker; 2001:513-523.
36. Preudhomme C, Lai JL, Plantier I, Demory JL, Zandecki M, Fenaux P. Cytogenetic and molecular remission in a case of acute myeloid leukaemia (AML) with inversion of chromosome 16 (Inv(16)) and Philadelphia chromosome (Ph). Br J Haematol. 1992;82:623-626.
37. Delaunay J, Leblanc T, Blaise D, et al. Prognostic significance of WBC, age, and cytogenetics in patients with core binding factor AML: a comparative study from the French AML Intergroup [abstract]. Blood. 2002;100:748a.
38. Kottaridis P, Gale R, Frew M, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [abstract]. Blood. 2001;98:1752-1759.
39. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
40. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
41. Care RS, Goodeve AC, Abu-Duhler FM, et al. Incidence and prognosis of c-kit and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias [abstract]. Blood. 2002;100:746a.
42. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A statistician's view. Br J Haematol. 2002;118:351-356.
43. Burnett AK. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - An adult treater's view. Br J Haematol. 2002;118:357-364.
44. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.